Vanda Pharmaceuticals (VNDA) Non-Current Assets (2010 - 2026)

Vanda Pharmaceuticals has disclosed Non-Current Assets across 17 years of filings, most recently posting $140.4 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $140.4 million, down 37.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $745.5 million (down 13.94% YoY), and the FY2025 annual result was $141.7 million, down 34.8% from the prior year.
• Non-Current Assets came in at $140.4 million for Q1 2026 at Vanda Pharmaceuticals, down from $141.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $233.6 million in Q3 2025 to a low of $105.0 million in Q3 2023.
• The 5-year median for Non-Current Assets is $141.7 million (2025), against an average of $165.7 million.
• Across the five-year window, Non-Current Assets surged 102.53% in 2024 and sank 37.35% in 2026, its largest moves.
• Vanda Pharmaceuticals' Non-Current Assets stood at $115.0 million in 2022, then jumped by 87.46% to $215.5 million in 2023, then advanced by 0.84% to $217.3 million in 2024, then plunged by 34.8% to $141.7 million in 2025, then decreased by 0.94% to $140.4 million in 2026.
• The last three Non-Current Assets figures came in at $140.4 million (Q1 2026), $141.7 million (Q4 2025), and $233.6 million (Q3 2025), per Business Quant data.